News Government wasted £1.3 billion on Cancer Drugs Fund, says st... The £1.3 billion of public expenditure on the old Cancer Drugs Fund (CDF) did not deliver value to patients or society, according to a new study.
News Janssen's Imbruvica recommended in CLL J&J unit awaiting decisions in two more blood cancer uses.
UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
News Janssen’s Imbruvica latest to gain NICE approval after price... Leukaemia drug latest cancer treatment to gain NICE approval
News Price cut brings ‘breakthrough’ NICE approval of Perjeta NICE says price cut made approval possible, despite continuing uncertainty about benefits
News NICE recommends Afinitor, Xalkori, as cancer drug review con... NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends